Chemokines network in bone metastasis: Vital regulators of seeding and soiling.

Szczegóły
Abstrakt

Tytuł:: Chemokines network in bone metastasis: Vital regulators of seeding and soiling.
Autorzy:: Sharma G; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Pothuraju R; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Kanchan RK; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Batra SK; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Siddiqui JA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198, USA. Electronic address: .
Źródło:: Seminars in cancer biology [Semin Cancer Biol] 2022 Nov; Vol. 86 (Pt 3), pp. 457-472. Date of Electronic Publication: 2022 Feb 03.
Typ publikacji:: Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
Język:: English
Imprint Name(s):: Publication: London : Academic Press
Original Publication: Philadelphia, PA, USA : Saunders Scientific Publications, W.B. Saunders Co., c1990-
MeSH Terms:: Chemokines*/metabolism
Bone Neoplasms*/genetics
Bone Neoplasms*/secondary
Male ; Humans ; Receptors, Chemokine/metabolism ; Cell Transformation, Neoplastic ; Tumor Microenvironment/genetics
References:: Blood. 2001 Jan 1;97(1):192-7. (PMID: 11133760)
Nature. 2005 Jan 20;433(7023):278-85. (PMID: 15662416)
Cancer Res. 2012 Jun 1;72(11):2768-79. (PMID: 22472119)
Stem Cells Transl Med. 2013 Dec;2(12):946-52. (PMID: 24191265)
Cell Commun Signal. 2020 Mar 26;18(1):48. (PMID: 32213179)
Physiology (Bethesda). 2016 May;31(3):233-45. (PMID: 27053737)
Immunol Rev. 2002 Oct;188:51-64. (PMID: 12445281)
Cell Cycle. 2019 Dec;18(24):3456-3471. (PMID: 31731888)
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61. (PMID: 9636188)
Exp Mol Med. 2017 Feb 17;49(2):e295. (PMID: 28209986)
Science. 2002 Oct 25;298(5594):850-4. (PMID: 12242449)
Oncotarget. 2014 Feb 15;5(3):599-612. (PMID: 24583601)
Cancer Immunol Res. 2014 Dec;2(12):1125-31. (PMID: 25480554)
Cancer Res. 2021 Jun 15;81(12):3295-3308. (PMID: 33853830)
Trends Mol Med. 2010 Mar;16(3):133-44. (PMID: 20163989)
Exp Mol Med. 2020 Aug;52(8):1239-1254. (PMID: 32801364)
Trends Cancer. 2015 Sep;1(1):76-91. (PMID: 28741564)
J Exp Med. 2002 Jun 3;195(11):1479-90. (PMID: 12045246)
Bone. 2019 Feb;119:8-12. (PMID: 29778716)
Clin Diagn Lab Immunol. 2003 Jan;10(1):133-9. (PMID: 12522051)
Cancer Lett. 2019 Jul 10;454:1-13. (PMID: 30974114)
Cancer Metastasis Rev. 2018 Dec;37(4):577-597. (PMID: 30465162)
J Immunol. 2009 Jun 1;182(11):6951-8. (PMID: 19454692)
Neoplasia. 2009 Nov;11(11):1235-42. (PMID: 19881959)
J Biochem Mol Biol. 2006 Nov 30;39(6):649-55. (PMID: 17129398)
Oncotarget. 2016 Jan 5;7(1):860-72. (PMID: 26497212)
Endocrinol Metab (Seoul). 2016 Jun;31(2):206-12. (PMID: 27184014)
Oncotarget. 2015 Jan 1;6(1):570-83. (PMID: 25402435)
Cell. 2017 Feb 9;168(4):670-691. (PMID: 28187288)
EJC Suppl. 2013 Sep;11(2):254-6. (PMID: 26217135)
Int J Oncol. 2009 Apr;34(4):881-95. (PMID: 19287945)
Cancer Res. 2016 Jul 15;76(14):4100-12. (PMID: 27197194)
Cancer Res. 2008 Dec 15;68(24):10367-76. (PMID: 19074906)
Expert Opin Ther Targets. 2010 Apr;14(4):435-42. (PMID: 20230195)
Cancer Res. 2008 Mar 15;68(6):1715-22. (PMID: 18339851)
Oncotarget. 2015 Jun 10;6(16):14165-78. (PMID: 25909173)
Cytokine. 2021 Jun;142:155479. (PMID: 33677228)
Cancer Res. 2002 Dec 15;62(24):7328-34. (PMID: 12499276)
Clin Cancer Res. 2005 Aug 15;11(16):5686-93. (PMID: 16115904)
J Biol Chem. 2012 Oct 19;287(43):36593-608. (PMID: 22927430)
Science. 2006 Sep 29;313(5795):1960-4. (PMID: 17008531)
Cancer Res. 2015 Sep 1;75(17):3479-91. (PMID: 26269531)
J Clin Invest. 2007 May;117(5):1175-83. (PMID: 17476347)
Cytokine. 2015 Aug;74(2):318-26. (PMID: 25742773)
Cell Rep. 2017 Apr 11;19(2):375-388. (PMID: 28402859)
Oncogene. 2019 Jun;38(23):4540-4559. (PMID: 30755731)
Transl Oncol. 2010 Dec 01;3(6):354-61. (PMID: 21151474)
Nature. 2019 May;569(7755):222-228. (PMID: 30971824)
Cancer Res. 2012 May 15;72(10):2522-32. (PMID: 22589273)
J Bone Miner Res. 2018 Dec;33(12):2099-2113. (PMID: 30476357)
Int J Mol Sci. 2019 Nov 28;20(23):. (PMID: 31795299)
Cell Commun Signal. 2020 May 29;18(1):82. (PMID: 32471499)
Front Cell Dev Biol. 2019 Sep 13;7:189. (PMID: 31572721)
Cancer Lett. 2018 Jan 1;412:69-80. (PMID: 28964785)
Front Oncol. 2020 Mar 10;10:293. (PMID: 32211326)
Sci Rep. 2016 Dec 06;6:38408. (PMID: 27922075)
J Craniofac Surg. 2017 Jul;28(5):1136-1141. (PMID: 28665863)
Cancer Res. 2004 Aug 1;64(15):5283-90. (PMID: 15289334)
Sci Rep. 2014 Aug 01;4:5911. (PMID: 25081383)
Nature. 2001 Apr 26;410(6832):1107-11. (PMID: 11323675)
Cold Spring Harb Perspect Biol. 2015 Jan 29;7(5):. (PMID: 25635046)
Nat Rev Cancer. 2016 Apr;16(4):201-18. (PMID: 27009393)
Tumour Biol. 2016 Oct;37(10):13425-13433. (PMID: 27460092)
Cancer Metastasis Rev. 2018 Mar;37(1):189-196. (PMID: 29380085)
Breast Cancer Res. 2020 Jan 10;22(1):4. (PMID: 31924241)
J Exp Med. 2003 Aug 4;198(3):433-42. (PMID: 12900519)
Nat Commun. 2018 Jan 2;9(1):32. (PMID: 29296022)
Cytokine Growth Factor Rev. 2018 Jun;41:10-17. (PMID: 29699936)
Proc Natl Acad Sci U S A. 1984 Jun;81(11):3511-5. (PMID: 6610177)
Oncol Rev. 2017 May 09;11(1):321. (PMID: 28584570)
Front Immunol. 2018 Mar 05;9:422. (PMID: 29556237)
Nat Rev Cancer. 2016 May 25;16(6):373-86. (PMID: 27220481)
J Exp Med. 2015 Jun 29;212(7):1043-59. (PMID: 26056232)
Front Immunol. 2019 Sep 13;10:2182. (PMID: 31572390)
Adv Wound Care (New Rochelle). 2013 Sep;2(7):327-347. (PMID: 24587971)
Dev Cell. 2019 May 6;49(3):375-391. (PMID: 31063756)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Nat Rev Immunol. 2012 Mar 22;12(4):239-52. (PMID: 22437937)
Oncol Lett. 2021 Oct;22(4):696. (PMID: 34457051)
Cancer Res. 2019 May 15;79(10):2580-2592. (PMID: 30952632)
Oncotarget. 2017 Feb 7;8(6):9739-9751. (PMID: 28039457)
J Exp Clin Cancer Res. 2010 Jun 22;29:80. (PMID: 20569497)
J Mol Med (Berl). 2015 Nov;93(11):1203-12. (PMID: 26275789)
Cancer Res. 2014 Dec 1;74(23):7103-14. (PMID: 25452256)
Clin Exp Metastasis. 2009;26(2):161-9. (PMID: 19002595)
Cytokine Growth Factor Rev. 2022 Apr;64:71-83. (PMID: 34836750)
Neoplasia. 2006 Jul;8(7):578-86. (PMID: 16867220)
Cell Death Dis. 2021 May 8;12(5):464. (PMID: 33966046)
Cytokine Growth Factor Rev. 2013 Aug;24(4):373-84. (PMID: 23787157)
Invest New Drugs. 2013 Jun;31(3):669-76. (PMID: 22828917)
Breast Cancer Res Treat. 2012 Feb;131(3):837-48. (PMID: 21479551)
Nat Med. 2017 Oct;23(10):1215-1219. (PMID: 28846098)
J Clin Invest. 2010 Feb;120(2):485-97. (PMID: 20051626)
Front Immunol. 2016 Jun 10;7:224. (PMID: 27375622)
Int J Cancer. 2018 Dec 1;143(11):3008-3018. (PMID: 30183073)
Ann Transl Med. 2020 Apr;8(7):482. (PMID: 32395526)
Cell. 2011 Oct 14;147(2):275-92. (PMID: 22000009)
Cancer Cell. 2012 Jul 10;22(1):91-105. (PMID: 22789541)
Cancer Res. 2019 Sep 15;79(18):4567-4576. (PMID: 31431464)
Front Endocrinol (Lausanne). 2018 Jun 07;9:313. (PMID: 29930538)
J Immunol. 2009 Dec 15;183(12):7825-31. (PMID: 19923448)
Oncol Rep. 2017 Feb;37(2):921-928. (PMID: 27922681)
Cancer Lett. 2016 Aug 1;378(1):23-32. (PMID: 27177471)
Nat Rev Mol Cell Biol. 2011 Dec 22;13(1):27-38. (PMID: 22189423)
Oncogene. 2000 May 15;19(21):2505-10. (PMID: 10851049)
Eur Urol. 2021 Jun;79(6):722-733. (PMID: 33153817)
Hepatology. 2013 Feb;57(2):829-39. (PMID: 23081697)
Blood. 2006 Mar 1;107(5):1761-7. (PMID: 16269611)
Int J Cancer. 2021 Mar 15;148(6):1308-1322. (PMID: 32761606)
Bone. 2014 Apr;61:176-85. (PMID: 24486955)
J Immunol. 2018 Oct 15;201(8):2510-2519. (PMID: 30158126)
J Thorac Oncol. 2019 May;14(5):e102-e103. (PMID: 31027743)
PLoS One. 2010 Jan 22;5(1):e8849. (PMID: 20107512)
Clin Cancer Res. 2013 Feb 1;19(3):643-56. (PMID: 23149820)
Oncogene. 2016 Mar 31;35(13):1716-24. (PMID: 26119946)
Cancer Gene Ther. 2022 Jan;29(1):10-21. (PMID: 33603130)
Antioxid Redox Signal. 2018 Jul 10;29(2):191-204. (PMID: 29113449)
Am J Respir Crit Care Med. 2015 Feb 15;191(4):437-47. (PMID: 25536148)
Anticancer Drugs. 2022 Feb 1;33(2):117-123. (PMID: 34561996)
Oncol Rep. 2009 Apr;21(4):1113-21. (PMID: 19288016)
J Oncol. 2019 Sep 19;2019:7407190. (PMID: 31641356)
Nat Rev Cancer. 2005 Aug;5(8):591-602. (PMID: 16056258)
Int J Cancer. 2009 Jan 15;124(2):326-32. (PMID: 19003962)
J Biol Chem. 2009 Oct 16;284(42):29087-96. (PMID: 19720836)
Nature. 2005 Dec 8;438(7069):820-7. (PMID: 16341007)
Bone. 2006 Apr;38(4):497-508. (PMID: 16337237)
Biochim Biophys Acta. 2016 Apr;1865(2):255-65. (PMID: 26993403)
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7260-4. (PMID: 2169622)
Bone. 2021 Feb;143:115762. (PMID: 33212319)
Anticancer Res. 2016 Jun;36(6):2631-7. (PMID: 27272771)
Br J Cancer. 2004 Nov 29;91(11):1970-6. (PMID: 15545974)
Int J Oncol. 2016 Mar;48(3):1085-94. (PMID: 26782945)
Mol Cancer Res. 2016 Jun;14(6):518-27. (PMID: 27001765)
Int J Oncol. 2018 Oct;53(4):1544-1556. (PMID: 30066854)
World J Gastroenterol. 2004 Feb 15;10(4):476-80. (PMID: 14966901)
Cancer Res. 2015 Oct 15;75(20):4312-21. (PMID: 26249173)
J Natl Cancer Inst. 2001 Nov 7;93(21):1638-43. (PMID: 11698568)
Crit Rev Immunol. 2004;24(3):205-28. (PMID: 15482255)
Pulm Pharmacol Ther. 2021 Apr;67:102001. (PMID: 33582208)
Bonekey Rep. 2014 Jan 08;3:481. (PMID: 24466412)
Cancer Res. 2018 Apr 15;78(8):2026-2039. (PMID: 29431639)
Einstein (Sao Paulo). 2015 Jul-Sep;13(3):469-73. (PMID: 26466066)
CA Cancer J Clin. 2021 Jul;71(4):359. (PMID: 34232515)
Cancers (Basel). 2020 Jan 24;12(2):. (PMID: 31991604)
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94. (PMID: 29115304)
Blood. 2001 May 15;97(10):3075-85. (PMID: 11342433)
Science. 1991 Dec 13;254(5038):1643-7. (PMID: 1840703)
Cancer Res. 2004 Jul 15;64(14):4693-8. (PMID: 15256432)
Clin Transl Oncol. 2021 Feb;23(2):378-388. (PMID: 32638214)
Cytokine. 2013 Oct;64(1):251-7. (PMID: 23876400)
J Cancer Res Clin Oncol. 2009 May;135(5):695-701. (PMID: 18972130)
Oncol Lett. 2018 Jun;15(6):9142-9150. (PMID: 29844821)
Cancer Res. 2009 Feb 15;69(4):1302-13. (PMID: 19190339)
EMBO Rep. 2001 Feb;2(2):151-6. (PMID: 11258708)
J Bone Miner Res. 2011 Feb;26(2):229-38. (PMID: 21254230)
Cell. 2019 Jun 13;177(7):1915-1932.e16. (PMID: 31130381)
Oncotarget. 2017 Oct 10;8(55):94591-94605. (PMID: 29212252)
J Exp Med. 2000 Sep 4;192(5):755-60. (PMID: 10974040)
Respir Res. 2020 Oct 31;21(1):287. (PMID: 33129326)
Cancer Res. 2006 May 15;66(10):4983-6. (PMID: 16707416)
Cancer Res. 1998 Aug 15;58(16):3491-4. (PMID: 9721846)
Annu Rev Pathol. 2011;6:121-45. (PMID: 20936937)
Curr Opin Support Palliat Care. 2015 Sep;9(3):261-7. (PMID: 26262831)
Semin Radiat Oncol. 2013 Oct;23(4):237-41. (PMID: 24012337)
J Cell Biochem. 2007 Jun 1;101(3):676-85. (PMID: 17216598)
J Invest Dermatol. 2004 Mar;122(3):685-90. (PMID: 15086554)
J Cell Sci. 2013 Feb 15;126(Pt 4):1032-45. (PMID: 23264747)
Cell Death Dis. 2018 Aug 29;9(9):880. (PMID: 30158589)
Nature. 2011 Jun 08;475(7355):222-5. (PMID: 21654748)
Curr Osteoporos Rep. 2016 Aug;14(4):151-8. (PMID: 27255469)
Nature. 2002 Dec 19-26;420(6917):860-7. (PMID: 12490959)
Bone. 2022 May;158:116113. (PMID: 34273634)
Lab Invest. 2017 Jun;97(6):669-697. (PMID: 28346400)
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s. (PMID: 17062708)
Front Oncol. 2019 Feb 06;9:40. (PMID: 30788286)
Cancer Biother Radiopharm. 2020 Nov;35(9):673-681. (PMID: 32228308)
Int J Mol Sci. 2017 Oct 02;18(10):. (PMID: 28974038)
Nature. 2017 Oct 12;550(7675):255-259. (PMID: 28953886)
Cold Spring Harb Perspect Med. 2020 Jul 1;10(7):. (PMID: 31570380)
Cell Commun Signal. 2020 Apr 7;18(1):59. (PMID: 32264958)
Cell Death Dis. 2021 Jan 7;12(1):48. (PMID: 33414415)
PLoS One. 2014 Jun 27;9(6):e100370. (PMID: 24971956)
Adv Cancer Res. 2010;106:91-111. (PMID: 20399957)
Clin Breast Cancer. 2018 Oct;18(5):e1117-e1122. (PMID: 29609951)
Curr Pharm Des. 2016;22(5):518-26. (PMID: 26601970)
Sci Rep. 2016 Feb 01;6:20250. (PMID: 26833095)
Neoplasia. 2010 Nov;12(11):899-905. (PMID: 21076615)
Tumour Biol. 2014 Aug;35(8):7765-73. (PMID: 24810923)
J Leukoc Biol. 2016 Jun;99(6):927-33. (PMID: 26908826)
Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7):. (PMID: 28716888)
FEBS J. 2018 Aug;285(16):2944-2971. (PMID: 29637711)
Cancer Lett. 2011 Sep 1;308(1):91-9. (PMID: 21601983)
Sci Rep. 2017 Nov 6;7(1):14513. (PMID: 29109519)
Oncol Lett. 2013 Dec;6(6):1577-1582. (PMID: 24260049)
J Natl Cancer Inst. 2005 Dec 21;97(24):1840-7. (PMID: 16368946)
Clin Exp Metastasis. 2010 May;27(5):331-40. (PMID: 20446021)
PLoS One. 2014 Jun 04;9(6):e99056. (PMID: 24897301)
Nat Rev Drug Discov. 2007 Apr;6(4):273-86. (PMID: 17396134)
Mol Cancer Res. 2018 Feb;16(2):296-308. (PMID: 29133591)
PLoS One. 2012;7(2):e31226. (PMID: 22359577)
Nat Rev Cancer. 2011 Jun;11(6):411-25. (PMID: 21593787)
Oncogene. 2019 Jan;38(3):332-344. (PMID: 30111818)
Cancer Res. 2005 Dec 1;65(23):11001-9. (PMID: 16322249)
Nat Rev Immunol. 2017 Sep;17(9):559-572. (PMID: 28555670)
Int J Cancer. 2016 Jan 15;138(2):417-27. (PMID: 26235173)
Cell Stem Cell. 2012 Jun 14;10(6):717-728. (PMID: 22704512)
Int J Cancer. 2012 Oct 1;131(7):1499-508. (PMID: 22212899)
J Gastrointest Surg. 2014 May;18(5):1040-8. (PMID: 24643495)
J Clin Med. 2019 Sep 25;8(10):. (PMID: 31557977)
Mol Cancer. 2021 Apr 4;20(1):62. (PMID: 33814009)
J Clin Invest. 2011 Apr;121(4):1298-312. (PMID: 21436587)
J Cell Physiol. 2010 Sep;224(3):626-35. (PMID: 20578239)
Cancer Res. 2009 Nov 1;69(21):8265-74. (PMID: 19861539)
Acta Orthop Scand Suppl. 1998 Oct;283:2-37. (PMID: 9856074)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Cell Death Discov. 2019 Apr 11;5:87. (PMID: 30993013)
Int J Clin Exp Pathol. 2015 Jul 01;8(7):8091-8. (PMID: 26339376)
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50. (PMID: 24127572)
J Recept Signal Transduct Res. 2015;35(6):600-4. (PMID: 26096166)
J Bone Miner Res. 2005 Feb;20(2):318-29. (PMID: 15647826)
CA Cancer J Clin. 2017 Jan;67(1):7-30. (PMID: 28055103)
Biochem Biophys Res Commun. 2002 Oct 4;297(4):700-13. (PMID: 12359210)
Nat Rev Immunol. 2011 Aug 25;11(9):597-606. (PMID: 21866172)
J Int Med Res. 2020 Apr;48(4):300060519883098. (PMID: 31884861)
Nat Med. 2017 Oct;23(10):1158-1166. (PMID: 28846099)
Nature. 2001 Mar 1;410(6824):50-6. (PMID: 11242036)
Oncol Rep. 2019 Mar;41(3):1911-1917. (PMID: 30628679)
Annu Rev Immunol. 1997;15:563-91. (PMID: 9143700)
Nat Med. 2017 Oct;23(10):1150-1157. (PMID: 28846097)
Clin Cancer Res. 2017 Sep 15;23(18):5358-5365. (PMID: 28539464)
J Biol Chem. 2008 Feb 15;283(7):4283-94. (PMID: 18057003)
Br J Haematol. 2015 Aug;170(4):472-86. (PMID: 25854627)
J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(2):2309499020915989. (PMID: 32634071)
J Bone Miner Res. 2010 Jun;25(6):1295-304. (PMID: 20200931)
Front Immunol. 2020 May 15;11:901. (PMID: 32499779)
Oncogene. 2012 Nov 8;31(45):4750-8. (PMID: 22266857)
Sci Rep. 2017 Nov 10;7(1):15300. (PMID: 29127344)
Front Endocrinol (Lausanne). 2017 Mar 29;8:49. (PMID: 28424660)
Nat Commun. 2020 Jan 3;11(1):69. (PMID: 31900418)
Front Pharmacol. 2020 Aug 19;11:1289. (PMID: 32973519)
Biochim Biophys Acta. 2014 Nov;1843(11):2563-2582. (PMID: 24892271)
PLoS One. 2016 Feb 24;11(2):e0150151. (PMID: 26910109)
J Biol Chem. 2002 Jun 14;277(24):21971-82. (PMID: 11923298)
Cancer Res. 2009 Feb 15;69(4):1685-92. (PMID: 19176388)
Sci Transl Med. 2016 May 25;8(340):340ra73. (PMID: 27225183)
Cancer Res. 2018 Apr 1;78(7):1657-1671. (PMID: 29358169)
Nat Cell Biol. 2020 Jan;22(1):38-48. (PMID: 31871321)
Immunity. 2006 Dec;25(6):977-88. (PMID: 17174120)
Front Immunol. 2019 Mar 06;10:379. (PMID: 30894861)
Cell Rep. 2019 Jul 9;28(2):302-311.e5. (PMID: 31291568)
Signal Transduct Target Ther. 2020 Feb 7;5(1):8. (PMID: 32296030)
Grant Information:: U01 CA185148 United States CA NCI NIH HHS
Contributed Indexing:: Keywords: Bone metastasis; Cancer; Chemokines; Drug resistance; Tumor heterogeneity
Substance Nomenclature:: 0 (Chemokines)
0 (Receptors, Chemokine)
Entry Date(s):: Date Created: 20220206 Date Completed: 20221122 Latest Revision: 20231102
Update Code:: 20240105
PubMed Central ID:: PMC9744380
DOI:: 10.1016/j.semcancer.2022.02.003
PMID:: 35124194
: Czasopismo naukowe

Full Text Finder

Chemokines are well equipped with chemo-attractive signals that can regulate cancer cell trafficking to specific organ sites. Currently, updated concepts have revealed the diverse role of chemokines in the biology of cancer initiation and progression. Genomic instabilities and alterations drive tumor heterogeneity, providing more options for the selection and metastatic progression to cancer cells. Tumor heterogeneity and acquired drug resistance are the main obstacles in managing cancer therapy and the primary root cause of metastasis. Studies emphasize that multiple chemokine/receptor axis are involved in cancer cell-mediated organ-specific distant metastasis. One of the persuasive mechanisms for heterogeneity and subsequent events is sturdily interlinked with the crosstalk between chemokines and their receptors on cancer cells and tissue-specific microenvironment. Among different metastatic niches, skeletal metastasis is frequently observed in the late stages of prostate, breast, and lung cancer and significantly reduces the survival of cancer patients. Therefore, it is crucial to elucidate the role of chemokines and their receptors in metastasis and bone remodeling. Here, we review the potential chemokine/receptor axis in tumorigenesis, tumor heterogeneity, metastasis, and vicious cycle in bone microenvironment.
Competing Interests: Declaration of Competing Interest SKB is co-founder of Sanguine Diagnostics and Therapeutics, Inc. Other authors declare no competing interests.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)

Informacja